In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Finding a Way Out of Pharma's Dealmaking Dilemma

Executive Summary

Big Pharma's being squeezed by deal prices, both for discovery and development assets. And with new capital coming in to fund earlier-stage projects, deals will only get more expensive. But a few forward thinking drug companies are making the seller's market work to their advantage, too, reducing financial exposure and business complexity while upgrading pipelines.

Related Content

Pharma's New Follow-On Strategy
Orphaning Biotech? The Impact of Biosimilars on Biotech Investment
Almirall: Adapting Primary-Care-focused R&D to a Specialist World
Biopharma: Reviewing 2007 to Forecast 2008
Therapeutic Area Partnerships: Faster, Earlier and Make Mine Cash
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Private Equity Comes to Discovery
Lilly's Chorus Experiment
The Large Molecule Future
No Dilution Necessary: The Promise of Project Financing


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts